Seborrheic Dermatitis: A Contemporary View of Pathogenesis, Diagnosis and Treatment – A Narrative Review of the Current Literature
DOI:
https://doi.org/10.12775/QS.2026.55.71002Keywords
seborrheic dermatitis, Malassezia, topical antifungals, calcineurin inhibitors, roflumilast, maintenance therapyAbstract
Background. Seborrheic dermatitis (SD) is a common, chronic, relapsing inflammatory dermatosis affecting sebum-rich areas, primarily the scalp, face, and intertriginous regions. Despite its generally benign nature, the relapsing course, visible distribution of lesions, and pruritus may substantially reduce patients’ quality of life.
Methods. A targeted literature review was conducted in the PubMed and Cochrane Library databases. Systematic reviews, meta-analyses, randomized clinical trials, and up-to-date narrative reviews on seborrheic dermatitis were included. The search terms comprised: “seborrheic dermatitis”, “Malassezia”, “topical treatment”, “anti-inflammatory treatment”, and “maintenance therapy”.
Results. Available evidence supports a multifactorial pathogenesis of SD, involving Malassezia yeasts, epidermal barrier dysfunction, and an abnormal host immune response. Topical antifungals remain the cornerstone of treatment, while short courses of anti-inflammatory therapy are effective during flares. Increasing emphasis is placed on maintenance strategies and steroid-sparing approaches. New nonsteroidal anti-inflammatory agents show promising efficacy and safety.
Conclusions. Long-term control of seborrheic dermatitis is best achieved through a stepwise therapeutic approach aimed at rapid management of flares and maintenance strategies that reduce relapse frequency
References
1. Dall’Oglio F, Nasca MR, Gerbino C, Micali G. An overview of the diagnosis and management of seborrheic dermatitis. Clin Cosmet Investig Dermatol. 2022;15:1537-1548. https://doi.org/10.2147/CCID.S284671
2. Turchin I, Albrecht L, Hanna S, et al. Current understanding of seborrheic dermatitis: presentation, diagnosis, and special populations. J Cutan Med Surg. 2025;29(4 Suppl):16S-23S. https://doi.org/10.1177/12034754251368828
3. Adalsteinsson JA, Kaushik S, Muzumdar S, Guttman-Yassky E, Ungar J. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol. 2020;29(5):481-489. https://doi.org/10.1111/exd.14091
4. Polaskey MT, Chang CH, Daftary K, Fakhraie S, Miller CH, Chovatiya R. The Global Prevalence of Seborrheic Dermatitis: A Systematic Review and Meta-Analysis. JAMA Dermatol. 2024;160(8):846-855. https://doi.org/10.1001/jamadermatol.2024.1987
5. Okokon EO, Verbeek JH, Ruotsalainen JH, Oksanen T, Kastarinen H. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015;2015(5):CD008138. https://doi.org/10.1002/14651858.CD008138.pub3
6. Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, Jyrkkä J, Oravilahti T, Rannanheimo PK, Verbeek JH. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;2014(5):CD009446. https://doi.org/10.1002/14651858.CD009446.pub2
7. Kim HO, Yang YS, Ko HC, Kim MB, Kwon KS. Maintenance Therapy of Facial Seborrheic Dermatitis with 0.1% Tacrolimus Ointment. Ann Dermatol. 2015;27(5):523-530. https://doi.org/10.5021/ad.2015.27.5.523
8. Saunte DML, Gaitanis G, Hay RJ. Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment. Front Cell Infect Microbiol. 2020;10:112. https://doi.org/10.3389/fcimb.2020.00112
9. Li J, Feng Y, Liu C, Li Q, Yu J, Li X, et al. Presence of Malassezia Hyphae Is Correlated with Pathogenesis of Seborrheic Dermatitis. Microbiol Spectr. 2022;10(1):e01169-21. https://doi.org/10.1128/spectrum.01169-21
10. Blauvelt A, Stein Gold L, Fowler J Jr, et al. Efficacy and safety of roflumilast foam 0.3% in adolescent and adult patients with seborrheic dermatitis: a phase 3 randomized clinical trial. J Am Acad Dermatol. 2024;90(5):986-993. https://doi.org/10.1016/j.jaad.2023.12.065
11. Alexis AF, Callis Duffin K, Zirwas MJ, et al. Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks. Am J Clin Dermatol. 2026;27(1):189-198. https://doi.org/10.1007/s40257-025-00984-2
12. Victoire A, Magin P, Coughlan J, van Driel ML. Interventions for infantile seborrhoeic dermatitis (including cradle cap). Cochrane Database Syst Rev. 2019;2019(3):CD011380. https://doi.org/10.1002/14651858.CD011380.pub2
13. Kim BS, Kim SH, Kim MB, Oh CK, Jang HS, Kwon KS. Treatment of Facial Seborrheic Dermatitis with Pimecrolimus Cream 1%: An Open-Label Clinical Study in Korean Patients. J Korean Med Sci. 2007;22(5):868-872. https://doi.org/10.3346/jkms.2007.22.5.868
14. Alsmeirat O, Lakhani S, Egaimi M, Idris OEA, Elkhalifa M, et al. The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials. Cureus. 2022;14(8):e27622. https://doi.org/10.7759/cureus.27622
15. Danby FW, Maddin WS, Margeson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo and placebo in the treatment of moderate to severe dandruff. J Am Acad Dermatol. 1993;29(6):1008-1012. https://doi.org/10.1016/0190-9622(93)70282-X
16. Shuster S, Fisher GH, Harris R, Binnell D. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol. 2005;141(1):47-52. https://doi.org/10.1001/archderm.141.1.47
17. Koller T, Willers C, Korting HC. A randomized, double-blind, placebo-controlled study of ketoconazole foam in seborrheic dermatitis. J Am Acad Dermatol. 2004;50(5):791-799. https://www.jaad.org/article/S0190-9622(03)03742-3/fulltext
18. Araya M, Kulthanan K, Jiamton S. Clinical characteristics and quality of life of seborrheic dermatitis patients in a tropical country. Indian J Dermatol. 2015;60(5):519. https://doi.org/10.4103/0019-5154.164410
19. Xuan M, Lu C, He Z, Zhang J. Clinical characteristics and quality of life in patients with seborrheic dermatitis: a cross-sectional study. Health Qual Life Outcomes. 2020;18(1):308. https://doi.org/10.1186/s12955-020-01558-y
20. Galizia G, Fabbrocini G, Cacciapuoti S, Monfrecola G. Seborrheic Dermatitis: From Microbiome and Skin Barrier Involvement to Emerging Approaches in Dermocosmetic Treatment. Cosmetics. 2024;11(6):208. https://doi.org/10.3390/cosmetics11060208
21. Cortés-Correa C, Piquero-Casals J, Chaparro-Reyes D, Garré Contreras A, Granger C, Peñaranda-Contreras E. Facial Seborrheic Dermatitis in HIV-Seropositive Patients: Evaluation of the Efficacy and Safety of a Non-Steroidal Cream Containing Piroctone Olamine, Biosaccharide Gum-2 and Stearyl Glycyrrhetinate - A Case Series. Clin Cosmet Investig Dermatol. 2022;15:483-488. https://doi.org/10.2147/CCID.S344807
22. Tomic S, Kuric I, Kuric TG, Popovic Z, Kragujevic J, Zubonja TM, et al. Seborrheic Dermatitis Is Related to Motor Symptoms in Parkinson’s Disease. J Clin Neurol. 2022;18(6):628-634. https://doi.org/10.3988/jcn.2022.18.6.628
23. Chernyshov PV, Vozianova SV, Chubar OV. Quality of Life of Infants, Toddlers and Preschoolers with Seborrhoeic, Allergic Contact and Atopic Dermatitis Before and During COVID-19 Pandemic. Dermatol Ther (Heidelb). 2021;11(6):2017-2026. https://doi.org/10.1007/s13555-021-00617-6
24. Navarro Triviño FJ, Velasco Amador JP, Rivera Ruiz I. Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis, and Emerging Therapies—A Narrative Review. Biomedicines. 2025;13(10):2458. https://doi.org/10.3390/biomedicines13102458
25. Borda LJ, Wikramanayake TC. Seborrheic Dermatitis and Dandruff: A Comprehensive Review. J Clin Investig Dermatol. 2015;3(2):10. https://doi.org/10.13188/2373-1044.1000019
26. Shen N, Chen W, Hu L, Huang J, Dong Q. Scalp seborrheic dermatitis demonstrates a skewing of Th1 activation: a proteomic study in lesional skin. Front Immunol. 2025;16:1638710. https://doi.org/10.3389/fimmu.2025.1638710
27. Ungar B, Manson M, Kim M, Gour D, Temboonnark P, Metukuru R, et al. Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis. J Am Acad Dermatol. 2025;92(6):1277-1287. https://doi.org/10.1016/j.jaad.2025.01.082
28. Piacentini F, Camera E, Di Nardo A, Dell’Anna ML. Seborrheic Dermatitis: Exploring the Complex Interplay with Malassezia. Int J Mol Sci. 2025;26(6):2650. https://doi.org/10.3390/ijms26062650
29. Barbosa V, Fernandes Melo D, Vañó-Galván S, Lutchmanen-Kolanthan V, Sant’Anna B, Leclerc-Mercier S, Reygagne P. A Comparative Randomized Clinical Study Assessing the Efficacy of a 1% Selenium Disulfide-Based Shampoo versus 2% Ketoconazole Shampoo in Subjects with Moderate to Severe Scalp Seborrheic Dermatitis. Skin Appendage Disord. 2024;10(6):497-504. https://doi.org/10.1159/000539209
30. Singh S, Paul D, Snehal A. Roflumilast in Dermatology: A Newer Phosphodiesterase-4 Inhibitor. Indian J Dermatol. 2025;70(1):38-41. https://doi.org/10.4103/ijd.ijd_261_24
31. Thurston AW Jr, Osborne DW, Snyder S, Higham RC, Burnett P, Berk DR, et al. Pharmacokinetics of roflumilast cream in chronic plaque psoriasis. Am J Clin Dermatol. 2023;24(2):315-324. https://doi.org/10.1007/s40257-022-00741-9
32. Fan T, Wang W, Wang Y, et al. PDE4 inhibitors: potential protective effects in inflammation and vascular diseases. Front Pharmacol. 2024;15:1407871. https://doi.org/10.3389/fphar.2024.1407871
33. Zirwas MJ, Draelos ZD, DuBois J, Kircik LH, Moore AY, Stein Gold L, et al. Efficacy of roflumilast foam, 0.3%, in patients with seborrheic dermatitis: a double-blind, vehicle-controlled phase 2a randomized clinical trial. JAMA Dermatol. 2023;159(6):613-620. https://doi.org/10.1001/jamadermatol.2023.0846
34. Abbas Z, Ghodsi SZ, Abedeni R. Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. Dermatol Pract Concept. 2016;6(3):11-16. https://doi.org/10.5826/dpc.0603a04
35. Alizadeh N, Monadi Nori H, Golchi J, et al. Comparison the efficacy of fluconazole and terbinafine in patients with moderate to severe seborrheic dermatitis. Dermatol Res Pract. 2014;2014:705402. https://doi.org/10.1155/2014/705402
36. Van TN, Thi NH. Efficacy of Oral Itraconazole in the Treatment of Seborrheic Dermatitis in Vietnamese Adults Patients. Open Access Maced J Med Sci. 2019;7(2):224-226. https://doi.org/10.3889/oamjms.2019.056
37. Ijaz N, Fitzgerald D. Seborrhoeic dermatitis. Br J Hosp Med (Lond). 2017;78(6):C88-C91. https://doi.org/10.12968/hmed.2017.78.6.C88
38. Cheong WK, Yeung CK, Torsekar RG, et al. Treatment of seborrhoeic dermatitis in Asia: a consensus guide. Skin Appendage Disord. 2016;1(4):187-196. https://doi.org/10.1159/000444682
39. Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: A comprehensive review. J Dermatolog Treat. 2019;30(2):158-169. https://doi.org/10.1080/09546634.2018.1473554
40. Sampaio ALSB, Mameri AC, Vargas TJ, Ramos-e-Silva M, Nunes AP, Carneiro SC. Seborrheic dermatitis. An Bras Dermatol. 2011;86(6):1061-1071; quiz 1072-1074. https://doi.org/10.1590/S0365-05962011000600002
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Gabriela Panek, Kacper Kość, Natalia Muzyka, Adam Prusek, Jakub Giersz, Magdalena Rumin, Remigiusz Piliński, Dominika Gosztyła, Amanda Abramowicz, Weronika Bukwald
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 56
Number of citations: 0
